Previous 10 | Next 10 |
Pfizer is a high-quality, high-yielding pharmaceutical company backed up by a robust drug portfolio. We appreciate Pfizer's decision to spinoff its Upjohn generics business, which was completed back in 2020, as the deal raised billions for Pfizer and ample synergies are expected going...
Viatris delivered strong results in Q2. Exchange rate headwinds were significant, but thanks to continued and successful operational rationalization and lower capital expenditures, the free cash flow guidance was maintained. VTRS is reducing debt as planned and could benefit from buyi...
Viatris Inc. (VTRS) Q2 2022 Earnings Conference Call August 08, 2022 08:30 AM ET Company Participants Bill Szablewski - Head of Global Capital Markets Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev Narula - Chief Financial Officer ...
The following slide deck was published by Viatris Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Viatris Inc. 2022 Q2 - Results - Earnings Call Presentation
The shares of the generic drugmaker, Viatris ( NASDAQ: VTRS ) traded ~4% higher in the pre-market Monday after its 2Q 2022 financials which failed to meet expectations for revenue as the company lowered the guidance to account for the rising U.S. dollar. Revenue for th...
Viatris ( NASDAQ: VTRS ) declares $0.12/share quarterly dividend , in line with previous. Forward yield 4.93% Payable Sept. 16; for shareholders of record Aug. 24; ex-div Aug. 23. See VTRS Dividend Scorecard, Yield Chart, & Dividend Growth. For further de...
Viatris press release ( NASDAQ: VTRS ): Q2 GAAP EPS of $0.26 beats by $0.07 . Revenue of $4.12B (-10.0% Y/Y) misses by $60M . For further details see: Viatris GAAP EPS of $0.26 beats by $0.07, revenue of $4.12B misses by $60M
Viatris Reports Strong Second Quarter 2022 Results PR Newswire Reports Total Revenues of $4.12 Billion ; U.S. GAAP Net Earnings of $314 Million ; Adjusted EBITDA of $1.48 Billion ; U.S. GAAP Net Cash Provided by Operating Activities of $803 Million ; ...
Viatris ( NASDAQ: VTRS ) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is $0.83 (-15.3% Y/Y) and the consensus Revenue Estimate is $4.18B (-8.7% Y/Y). Over the last 1 year, VTRS has beaten EPS estim...
ANIP , APRN , ASRT , BNTX , CLVS , D , DCTH , DTIL , ELAN , ENR , FREY , GOLD , HE , HEP , ITUB , KNDI , KOS , LINC , OTCPK:LKNCY , OSG , PDSB , PLTR , PRTY , RDWR , RETA , SOHU , TGN...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...